In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Challenges in the evaluation and management of aortic stenosis

Session presentations
  • Asymptomatic aortic stenosis. Presented by R Rosenhek (Vienna, AT) See the slides
  • Aortic stenosis with hypertension: the double loaded ventricle. Presented by J Bermejo (Madrid, ES) See the slides
  • Aortic stenosis with concomitant mitral regurgitation. Presented by P Unger (Brussels, BE) See the slides
  • Low-flow low gradient aortic stenosis: new challenges, new solutions. Presented by P Pibarot (Quebec, CA) See the slides
Valvular Heart Diseases


This session addressed some of the current clinical challenges we face in caring for adults with calcific aortic valve disease. 

Raphael Rosenhek discussed the management of asymptomatic patients with severe aortic stenosis (AS).  When severe AS is present, the first step is to ensure the patient is truly asymptomatic by a careful clinical history, consideration of exercise testing if symptom status is unclear and measurement of serum BNP levels.  Even if truly asymptomatic,  predictors of progression to symptom onset include a higher aortic velocity, more calcified valve, more rapid hemodynamic progression (over 0.3 m/s/year) and older age. The 2012 ESC Guidelines for Valvular Heart Disease recommend aortic valve replacement (AVR) in asymptomatic adults with severe AS when left ventricular (LV) systolic dysfunction is present or when symptoms are provoked on exercise testing. AVR also may be considered when there is severe valve calcification, rapid hemodynamic progression or very severe AS with an aortic velocity over 5.5 m/s. However, a careful assessment of the risk-benefit ratio of AVR is especially important in the asymptomatic patient. 

Javier Bermejo then addressed the problem of aortic stenosis with hypertension or the “double loaded” ventricle. His take home messages were that hypertension may affect evaluation of AS severity and that control of blood pressure is important in adults with AS. Treatment should be monitored closely but blood pressure control with angiotensin converting enzyme inhibitors or receptor blockers is associated with improved clinical outcomes.
 
Philippe Unger then discussed management of the patient with AS and concomitant mitral regurgitation (MR).  In this situation, the mechanism of mitral regurgitation must be determined because functional MR is more likely to improve after relief of AS than organic MR, which likely will require an additional mitral valve procedure. Further clinical studies on this challenging clinical problem are needed.

The session concluded with a presentation by Philippe Pibarot on low-flow low-gradient aortic stenosis. In a subset of AS patients, transaortic volume flow rate is reduced, either due to LV systolic dysfunction with a low ejection fraction or due to a small ventricular chamber with a preserved ejection fraction. Quantification of AS severity is challenging in this situation because the aortic velocity and pressure gradient are lower than expected for the decrease in valve area. In symptomatic patients, it is important to identify those with severe AS and low-gradient because these patients benefit from AVR. The typical patient with low-output low-gradient severe AS with normal ejection fraction is an elderly woman with severe LV hypertrophy and a calcified aortic valve.

References


143

SessionTitle:

Challenges in the evaluation and management of aortic stenosis

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.